Conference report: Atorvastatin does not reduce mortality in COVID-19

In the INSPIRATION study (n=605), atorvastatin 20mg daily did not reduce the incidence of the composite endpoint (30-day venous or arterial thrombosis, treatment with ECMO, or all-cause mortality) in patients critically ill with Covid-19 (32.7% v 36.3% placebo; p=0.22).

Medicom